论文部分内容阅读
目的:探究胸腺肽联合抗生素在老年慢性阻塞性肺疾病急性加重治疗中的价值。方法:选取本院2013年1月—2014年1月确诊的76例老年慢性阻塞性肺疾病急性加重患者作为研究对象,将全部患者随机分为两组,每组38例。对照组采用头孢他啶等常规治疗,观察组在对照组的基础上加用胸腺肽注射液进行治疗。结果:观察组的总有效率94.74%,明显高于对照组的65.79%(P<0.05);两组患者治疗后的临床症状评分及生活质量评分比较,差异具有统计学意义(P<0.05)。两组患者在治疗前后一秒用力呼气容积(FEV1)(L)与FEV1%的比较,差异具有统计学意义(P<0.05)。经过治疗后FEV1(L)与FEV1%比较,差异无统计学意义(P>0.05);无过敏、皮疹以及肝功能损害等不良反应出现。结论:胸腺肽联合抗生素在老年慢性阻塞性肺疾病急性加重治疗效果显著,安全性较高。
Objective: To investigate the value of thymosin combined with antibiotics in the treatment of senile chronic obstructive pulmonary disease. Methods: A total of 76 elderly patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) diagnosed in our hospital from January 2013 to January 2014 were enrolled in this study. All patients were randomly divided into two groups (n = 38 in each group). The control group was treated with ceftazidime. The observation group was treated with thymosin injection on the basis of the control group. Results: The total effective rate in the observation group was 94.74%, which was significantly higher than that in the control group (65.79%, P <0.05). The clinical symptom scores and quality of life scores of the two groups were statistically significant (P <0.05) . The difference of FEV1 (L) and FEV1% between the two groups before and after treatment was statistically significant (P <0.05). After treatment, there was no significant difference in FEV1 (L) and FEV1% (P> 0.05); no adverse reactions such as allergy, rash and liver dysfunction occurred. Conclusion: Thymosin combined with antibiotics in elderly patients with acute obstructive pulmonary disease treatment of significant effect, high safety.